ERBB2 and colorectal carcinoma: Many researchers have exploited the drugs selected in PDX models on patients and tested their efficacy.179 Afatinib, a TKI targeting HER2 and EGFR, outstood the drug sensitivity test in a PDX model derived from a CRC patient resistant to multiple lines of treatment; the patient used afatinib subsequently and achieved progression-free survival for three months.180 Coussy et al. used PDX models to study the therapeutic choices for patients with luminal androgen receptor triple-negative breast cancer resistant to enzalutamide and discovered significant enrichment in PIK3CA and AKT1 mutations.